Esperion Therapeutics | ESPR - Operating Profit

Stock Price
3.49
Daily Change
0.10 2.80%
Monthly
-1.83%
Yearly
85.37%
Q1 Forecast
2.70

Esperion Therapeutics reported $-16.03M in Operating Profit for its fiscal quarter ending in September of 2024.





Operating Profit Change Date
AbbVie USD 5.81B 1.23B Dec/2025
Alnylam Pharmaceuticals USD -29.96M 13.76M Sep/2025
Alterity Therapeutics Limited AUD -7.77M 2.99M Jun/2023
Amarin USD -1.7M 8.47M Sep/2025
Amgen USD 3.96B 464M Dec/2025
Biogen USD 659.6M 192.2M Sep/2025
BioMarin Pharmaceutical USD -31.69M 308.58M Sep/2025
Cipla INR 9.77B 6.21B Dec/2025
CSL USD 666M 1.31B Jun/2025
Cytokinetics USD -166.76M 55.25M Sep/2025
Daiichi Sankyo JPY 89.54B 42.01B Dec/2025
Eli Lilly USD 8.99B 599.9M Dec/2025
Esperion Therapeutics USD -16.03M 18.6M Sep/2024
Geron USD -13.89M 1.43M Sep/2025
Grifols EUR 411.56M 15.51M Sep/2025
Halozyme Therapeutics USD 217.92M 15.48M Sep/2025
Heron Therapeutics USD -5.66M 782K Sep/2024
Ionis Pharmaceuticals USD -160.18M 300.02M Sep/2025
Merck USD 6.24B 318M Dec/2025
Minerva Neurosciences USD -21.85M 17.48M Dec/2024
Moderna USD -260M 647M Sep/2025
Nektar Therapeutics USD -34.34M 15.43M Sep/2024
Pfizer USD 4.65B 3.99B Dec/2025
PTC Therapeutics USD 3.49M 38.35M Sep/2025
Puma Biotechnology USD 22.08M 24.26M Sep/2024
Regeneron Pharmaceuticals USD 898.6M 211.3M Dec/2025
Sanofi EUR 1.7B 2.17B Dec/2025
Sarepta Therapeutics USD -62.88M 178.46M Sep/2025
United Therapeutics USD 389.3M 112.4M Sep/2025
Vanda Pharmaceuticals USD -40.66M 29.66M Dec/2024